Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03812380 · ClinicalTrials.gov registry record · Phase 3
Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate
A Phase 3 study, sponsored by University of Texas Southwestern Medical Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 62
- Enrollment target
NCT03812380 is a Phase 3 study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 62 participants.
The verdict
NCT03812380, a Phase 3 study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 62 participants
- Enrollment target
Study Summary
Proton pump inhibitors (PPIs) are widely used for the control of gastric ulcer-gastritis, erosive esophagitis (gastroesophageal reflux disease), peptic ulcer disease (duodenal ulcer), and heartburn. Despite their efficacy, their use has been implicated in possibly causing fragility fractures (osteoporosis), hypomagnesemia (magnesium deficiency) and increased risk of chronic kidney disease (CKD). The current trial represents the investigators' ongoing effort to discern whether these complications could be averted by effervescent calcium magnesium citrate (EffCaMgCit).
Interventions
- OTHER Placebo
- DRUG EffCaMgCit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2019-01-01 |
| Est. Completion | 2021-08-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03812380
The ClinicalTrials.gov registry entry for NCT03812380 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03812380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03812380 about?
NCT03812380 is a clinical study titled "Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate". Proton pump inhibitors (PPIs) are widely used for the control of gastric ulcer-gastritis, erosive esophagitis (gastroesophageal reflux disease), peptic ulcer disease (duodenal ulcer), and heartburn. Despite their efficacy, their use has been implicated in possibly causing fragility fractures (osteop...
What is the current status of trial NCT03812380?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 62 participants. The study started on 2019-01-01. Estimated completion is 2021-08-11.
What interventions are being tested in trial NCT03812380?
The interventions under investigation include: Placebo (OTHER), EffCaMgCit (DRUG).
Who is sponsoring clinical trial NCT03812380?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.